Regulus Therapeutics Inc.
RGLSDelisted Jun 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001505512
Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 75
- Q1 2025, +7 vs. previous quarter
- 13F value
- $107.0M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding RGLS, Q1 2025
No superinvestor reported holding RGLS at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by Regulus Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Klassen PrestonPresident & Head of R & D | PPurchase | +12.0K | $7.99 | +$95.9K | +33.3%48.1K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Hagan Joseph PChief Executive Officer | PPurchase | +50.0K | $1.09 | +$54.5K | +23.7%260.8K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Baltimore DavidDirector | PPurchase | +19.6K | $1.06 | +$20.8K | +766.3%22.2K after | |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Hagan Joseph PChief Executive Officer | SSale | −127.1K | $1.26 | −$160.1K | −37.6%210.8K after | 2 lots10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Aker Christopher RaySr. VP & General Counsel | SSale | −43.6K | $1.26 | −$55.0K | −46.8%49.5K after | 2 lots10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13-14 | 2 days | Calsada CrispinaChief Financial Officer | SSale | −43.8K | $1.26 | −$55.2K | −49.1%45.5K after | 2 lots10b5-1 |
| Jan 15, 2025 (view filing) | Jan 13 | 2 days | Klassen PrestonPresident & Head of R & D | SSale | −31.4K | $1.26 | −$39.6K | −46.6%36.1K after | 10b5-1 |
| Jul 29, 2024 (view filing) | Jul 25 | 4 days | Collier Kathryn JDirector | PPurchase | +4.00K | $1.82 | +$7.28K | +146.0%6.74K after | |
| Jan 18, 2024 (view filing) | Jan 18 | Same day | Calsada CrispinaChief Financial Officer | SSale | −5.47K | $1.19 | −$6.51K | −48.6%5.78K after | |
| Jan 18, 2024 (view filing) | Jan 18 | Same day | Aker Christopher RaySr. VP & General Counsel | SSale | −5.47K | $1.19 | −$6.51K | −35.2%10.1K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in Regulus Therapeutics Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 15,819,863 | $39.2M | 0.08% | +2,967,209+23.1% | Added |
| NEA Management Company, LLC | 6,467,802 | $11.3M | 0.87% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 4,637,076 | $8.11M | 1.76% | −211,726−4.4% | Reduced |
| BlackRock, Inc. | 4,170,515 | $7.30M | 0.00% | −66,054−1.6% | Reduced |
| Vanguard Group Inc | 3,952,120 | $6.92M | 0.00% | −14,971−0.4% | Reduced |
| Deep Track Capital, LP | 3,262,564 | $5.71M | 0.18% | 00.0% | Unchanged |
| Vivo Capital, LLC | 2,696,426 | $4.72M | 0.62% | −2,303,574−46.1% | Reduced |
| Baker Bros. Advisors LP | 2,694,044 | $4.71M | 0.05% | +2,694,044 | New |
| Point72 Asset Management, L.P. | 1,968,293 | $3.44M | 0.01% | +1,073,165+119.9% | Added |
| Geode Capital Management, LLC | 1,300,818 | $2.28M | 0.00% | +21,487+1.7% | Added |